ArticleBehavioural brain research2017
A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
Article in Behavioural brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans.Hormones and behavior · 2018Trial
- Molecular and neural circuit mechanisms of parvalbumin (PV) neurons in depression: Insights and advances.iScience · 2026Review
- Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers.Communications medicine · 2026Article
- Antidepressants and the endogenous opioid system.Biochemical pharmacology · 2025Review
- Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?The American journal of psychiatry · 2025Review
- Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov.Translational psychiatry · 2024Review
- Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.Drug and alcohol dependence · 2023Article
- Activation of the Mu-Delta Opioid Receptor Heteromers Blocks Morphine Rewarding Effects.The international journal of neuropsychopharmacology · 2023Article
- Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice.The Journal of pharmacology and experimental therapeutics · 2023Article
- Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.Psychopharmacology · 2022Article
- Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.Advances in drug and alcohol research · 2022Article
- Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors.Pharmacological reports : PR · 2021Review
- When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.The American journal of drug and alcohol abuse · 2021Article
- Advances in novel molecular targets for antidepressants.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine.Advances in drug and alcohol research · 2021Article
- Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.The Journal of pharmacology and experimental therapeutics · 2020Article
- The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.Molecular biology reports · 2020Review
- Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine.British journal of pharmacology · 2019Article
- Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.The Journal of pharmacology and experimental therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa (KOR) opioid receptors, has been shown to produce behavioral responses in rodents that are similar to those of antidepressant and anxiolytic drugs. Although recent studies have identified KORs as a primary mediator of BPN's effects in rodent models of depressive-like behavior, the role of MORs in BPN's behavioral effects has not been as well explored. The current studies investigated the role of MORs in mediating conditioned approach behavior in the novelty-induced hypophagia (NIH) test, a behavioral measure previously shown to be sensitive to chronic treatment with antidepressant drugs. The effects of BPN were evaluated in the NIH test 24h post-administration in mice with genetic deletion of the MOR (Oprm1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.